

Table SI. Baseline characteristics of 24,771 patients stratified by number of BCCs treated with curettage at study inclusion (first registration of BCC C±E treatment).

	All patients N=24,771 (100%)	Patients with 1 tumour N=20,893 (84.3%)	Patients with ≥2 tumours N=3,878 (15.7%)
Sex, n (%)			
Female	12533 (50.6%)	10751 (51.5%)	1782 (46.0%)
Male	12238 (49.4%)	10142 (48.5%)	2096 (54.0%)
Annual disposable income, n (%)			
1st quartile (<281,249 DKK)	6193 (25.0%)	5233 (25.0%)	960 (24.8%)
2nd - 3rd quartile (281,250 - 634,697)	12385 (50.0%)	10421 (49.9%)	1964 (50.6%)
4th quartile (>634,782DKK)	6193 (25.0%)	5239 (25.1%)	954 (24.6%)
Highest obtained education, n (%)			
Short	6304 (25.4%)	5340 (25.6%)	964 (24.9%)
Medium	10191 (41.1%)	8573 (41.0%)	1618 (41.7%)
Long	7966 (32.2%)	6724 (32.2%)	1242 (32.0%)
Unknown	310 (1.3%)	256 (1.2%)	54 (1.4%)
Number of hospital-registered diagnoses (median, IQR)	2.0 (1.0-3.0)	2.0 (1.0-3.0)	2.0 (1.0-3.0)

BCC=basal cell carcinoma; C±E= curettage with or without electrodesiccation; IQR=interquartile range; n=number.

Table SII. BCC tumour characteristics stratified by registration of follow-up or no follow-up after C±E treatment.

	Tumours without follow-up N= 37,145	Tumours with follow-up N=47,358
Age (years), median (IQR)	74.3 (65.6, 81.2)	72.2 (64.2, 78.0)
Anatomical locations, n (%)		
Trunk	7642 (20.6%)	10743 (22.7%)
Extremities	2539 (6.8%)	3140 (6.6%)
Head and neck	10811 (29.1%)	11729 (24.8%)
Unspecified	16153 (43.5%)	21746 (45.9%)
Histological subtype, n (%)		
Nodular	21088 (56.8%)	26050 (55.0%)
Superficial	3490 (9.4%)	4020 (8.5%)
Aggressive subtypes	333 (0.9%)	404 (0.9%)
Unspecified	12234 (32.9%)	16884 (35.7%)
Tumour size, n (%)		
Under 10mm	23999 (64.6%)	36431 (76.9%)
Over 10mm	4494 (12.1%)	7862 (16.6%)
Unspecified	8652 (23.3%)	3065 (6.5%)

Aggressive subtypes were infiltrated, morpheaform, micronodular or basosquamous. BCC=basal cell carcinoma; C±E= curettage with or without electrodesiccation; IQR=interquartile range; n=number.